Industry News
Pharmaceutical Industry News
PharmaTher fleshes out ketamine delivery portfolio with deal for on-body injector
PharmaTher fleshes out ketamine delivery portfolio with deal for on-body injector ntaylor Fri, 05/27/2022 - 06:51
GSK’s ViiV adds a new, unexpected demographic to Dovato campaign
GSK's ViiV adds a new, unexpected demographic to Dovato campaign sharon.coey Fri, 05/27/2022 - 06:11
Idorsia taps more star power, enlisting actor Taye Diggs to pitch newly launched insomnia drug Quviviq
Idorsia taps more star power, enlisting actor Taye Diggs to pitch newly launched insomnia drug Quviviq nmissakian Thu, 05/26/2022 - 18:29
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug kdunleavy Thu, 05/26/2022 - 16:13
The FDA is busy busting up drug counterfeiting rings—but is it doing enough to protect patients?
The FDA is busy busting up drug counterfeiting rings—but is it doing enough to protect patients? fkansteiner Thu, 05/26/2022 - 15:19
‘The Top Line’ podcast: How biopharma is tackling the monkeypox outbreak, insight on nominations for our Fierce 15 list, plus this week’s headlines
'The Top Line' podcast: How biopharma is tackling the monkeypox outbreak, insight on nominations for our Fierce 15 list, plus this week's headlines tcarey Thu, 05/26/2022 - 14:15
ASCO: Bristol Myers delves into Opdualag’s LAG-3 melanoma win in key populations
ASCO: Bristol Myers delves into Opdualag's LAG-3 melanoma win in key populations aliu Thu, 05/26/2022 - 12:18
Sanofi, Regeneron’s Libtayo scores UK watchdog’s approval in common form of skin cancer
Sanofi, Regeneron's Libtayo scores UK watchdog's approval in common form of skin cancer kdunleavy Thu, 05/26/2022 - 11:02
ASCO: Merck touts Keytruda’s ‘convergent’ benefits across postsurgery lung cancer patient groups
ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups aliu Thu, 05/26/2022 - 10:34
Servier’s Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer
Servier's Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer esagonowsky Thu, 05/26/2022 - 10:03
Pfizer antiviral usage is ticking up in the US as uptake of Merck, AZ drugs remains limited
Pfizer antiviral usage is ticking up in the US as uptake of Merck, AZ drugs remains limited fkansteiner Thu, 05/26/2022 - 10:00
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data aliu Thu, 05/26/2022 - 05:35
Eli Lilly plots $2.1B manufacturing expansion at America’s crossroads, with 500 new hires
Eli Lilly plots $2.1B manufacturing expansion at America's crossroads, with 500 new hires fkansteiner Wed, 05/25/2022 - 13:48
ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population
ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population aliu Wed, 05/25/2022 - 12:14
Teva, AbbVie’s Allergan hand over $161M to settle opioid lawsuit in West Virginia
Teva, AbbVie's Allergan hand over $161M to settle opioid lawsuit in West Virginia zbecker Wed, 05/25/2022 - 12:01
Kadmon consultant charged with insider trading ahead of biotech’s $1.9B sale to Sanofi: SEC
Kadmon consultant charged with insider trading ahead of biotech's $1.9B sale to Sanofi: SEC fkansteiner Wed, 05/25/2022 - 10:45
Verrica Pharma’s viral skin condition drug gets rejected—again, with its CMO flagged for deficiencies
Verrica Pharma’s viral skin condition drug gets rejected—again, with its CMO flagged for deficiencies zbecker Wed, 05/25/2022 - 10:33
Pfizer reveals plan to make its products available to 45 poor countries at not-for-profit cost
Pfizer reveals plan to make its products available to 45 poor countries at not-for-profit cost kdunleavy Wed, 05/25/2022 - 09:57
Kyowa Kirin goes for the glow to bring awareness to rare bone disease XLH
Kyowa Kirin goes for the glow to bring awareness to rare bone disease XLH sharon.coey Wed, 05/25/2022 - 09:30
J&J’s Momenta calls infringement against Viatris’ Copaxone generic, but why now?
J&J's Momenta calls infringement against Viatris' Copaxone generic, but why now? fkansteiner Wed, 05/25/2022 - 09:05